Chugai Pharmaceutical Co., Ltd.
CHGCF
$42.03
-$1.06-2.45%
OTC PK
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.54% | 13.20% | -3.34% | 23.72% | -37.49% |
| Total Other Revenue | 55.41% | 14.55% | 18.53% | -13.79% | 39.72% |
| Total Revenue | 5.11% | 13.44% | -0.93% | 18.58% | -32.37% |
| Cost of Revenue | 5.61% | -8.12% | 8.08% | 17.26% | -57.04% |
| Gross Profit | 4.90% | 23.23% | -4.41% | 19.17% | -9.17% |
| SG&A Expenses | -8.77% | 12.71% | 12.25% | 0.21% | -4.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 97.06% | 245.74% | -1,480.33% | -193.72% | 113.00% |
| Total Operating Expenses | 5.20% | -1.81% | 4.99% | 7.87% | -42.90% |
| Operating Income | 5.02% | 35.53% | -6.82% | 33.27% | -9.45% |
| Income Before Tax | 10.91% | 33.96% | -7.58% | 32.45% | -10.68% |
| Income Tax Expenses | 21.05% | 20.95% | -10.69% | 47.49% | -13.18% |
| Earnings from Continuing Operations | 6.85% | 38.78% | -6.27% | 27.30% | -9.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.85% | 38.78% | -6.27% | 27.30% | -9.79% |
| EBIT | 5.02% | 35.53% | -6.82% | 33.27% | -9.45% |
| EBITDA | 5.17% | 28.91% | -6.79% | 33.13% | -9.55% |
| EPS Basic | 6.85% | 38.85% | -6.26% | 27.28% | -9.80% |
| Normalized Basic EPS | 10.91% | 34.03% | -7.60% | -- | -10.69% |
| EPS Diluted | 6.85% | 38.83% | -6.26% | 27.28% | -9.80% |
| Normalized Diluted EPS | 10.91% | 34.03% | -7.57% | -- | -10.69% |
| Average Basic Shares Outstanding | 0.00% | -0.05% | 0.01% | 0.01% | 0.02% |
| Average Diluted Shares Outstanding | 0.00% | -0.03% | 0.00% | 0.01% | 0.02% |
| Dividend Per Share | -- | 24.99% | 31.63% | -- | -- |
| Payout Ratio | -- | -- | -0.07% | -- | -0.02% |